Longevity Clinics Guide
Menu

Method and trust

How we check licencesReview policyFor clinicsAboutDisclosuresContact

Treatments · 1 clinic in 1 country · checked 18 Oct 2026

Senolytics: evidence, regulation and where it is offered

Senolytics are experimental drugs designed to clear senescent cells, which are cells that have stopped dividing but stay active in the body. Our evidence label for it is Emerging. Early human evidence; benefits for healthy ageing not yet shown. 1 clinic we list offer it, in the United States.

The US National Institutes of Health describes senolytics as experimental drugs. Studies in people have tested dasatinib, a leukaemia medicine, together with quercetin. Some people take quercetin or fisetin on their own as anti-ageing agents, and the senior author of a 2024 trial has cautioned against this.

EMERGING

What the evidence says

Prescription status: a prescription-only treatment. We show no prices for it where the rules forbid advertising prescription medicines.

Human studies of senolytics are small and early. The first study in people, in 2019, gave dasatinib and quercetin to 14 people with a lung disease, idiopathic pulmonary fibrosis. It had no comparison group. Walking and other physical tests improved, but lung function did not change.

In a 2024 randomised trial in 60 women past the menopause, 20 weeks of dasatinib plus quercetin did not reduce the main marker of bone loss compared with a control group. Women with more senescent cells showed some changes in bone markers (Mayo Clinic, 2024). These trials looked at a lung disease and at bone loss. They do not show that senolytics help healthy ageing.

Regulators and prescription status

Dasatinib is a prescription medicine licensed for some types of leukaemia (MedlinePlus). Using it as a senolytic is off-label, meaning for a use it is not licensed for.

Emerging means: Early human evidence; benefits for healthy ageing not yet shown.

What regulators say

CountryNoteSource
United StatesNo regulator statement recorded yet.

Where it is offered

New York1 clinic

Published prices

No price that may be shown is published by the clinics we list.

Safety and questions to ask

Serious side effects of dasatinib include unusual bruising or bleeding, shortness of breath, chest pain and a fast or irregular heartbeat (MedlinePlus). In the 2019 lung study, one person had a serious adverse event. The most common side effects were breathing symptoms, skin irritation or bruising, and stomach discomfort.

  1. Which product is proposed, and is it a prescription medicine where I live?
  2. Who prescribes it, and what checks come first?
  3. What side effects should I watch for, and who do I call?
  4. Is it part of a registered clinical trial?
  5. Does it interact with any medicines I take?

Sources